Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Biomodal Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. The busiest examiner for the company is WILDER, CYNTHIA B, who is handling the 1 pending action currently in the system.
The company's prosecution footprint is highly concentrated, with only 1 pending office action and 1 distinct examiner involved. Because the entire current workload is within 1 distinct art unit, the prosecution strategy is focused on a single technical area. Success for the portfolio at this stage depends on the specific requirements and feedback from WILDER, CYNTHIA B regarding this 1 pending action. Practitioners should analyze the examination history of WILDER, CYNTHIA B within the 1 distinct art unit to anticipate potential rejections. Since there are no other pending actions, the company can dedicate its full attention to resolving this 1 pending office action efficiently. A tailored response that addresses the specific concerns of the 1 distinct examiner will be critical for achieving an allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 1 | 71.0% | +26.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19552942 | USE OF 5-HYDROXYMETHYCYTOSINE OR 5-METHYLCYTOSINE FOR DISEASE DETECTION | WILDER, CYNTHIA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19552942 | USE OF 5-HYDROXYMETHYCYTOSINE OR 5-METHYLCYTOSINE FOR DISEASE DETECTION | WILDER, CYNTHIA B | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19552942 | USE OF 5-HYDROXYMETHYCYTOSINE OR 5-METHYLCYTOSINE FOR DISEASE DETECTION | WILDER, CYNTHIA B | 1681 | §101§103§112 | Non-Final OA | — | Pending | Feb 27, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial